相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Two studies following over 6,000 adults for 10 years found coronary artery calcium scores only modestly improved cardiovascular risk prediction when added to the PREVENT calculator. - In patients classified as borderline or intermediate risk by PREVENT, calcium scoring produced more meaningful reclassification of who would and would not have a heart attack or stroke. - Researchers cautioned that routine calcium scanning in low-risk people brings unnecessary radiation, testing and costs, while high-risk patients should start statins regardless of scan results. - A separate JACC analysis found some patients with a calcium score of zero still had events, indicating CAC should not be used to withhold statin therapy.
- Northwestern Medicine researchers discovered that montelukast, a widely-used asthma medication, can restore immunotherapy sensitivity in treatment-resistant cancers by blocking the CysLTR1 receptor. - The study found that tumors hijack CysLTR1 to reprogram neutrophils into immunosuppressive cells, effectively shielding cancer from immune attack. - In preclinical models of triple-negative breast cancer and other aggressive cancers, montelukast slowed tumor growth and improved survival when combined with immunotherapy. - The findings offer particular significance for India, where approximately 100,000 women are diagnosed with triple-negative breast cancer annually and access to experimental therapies remains limited.
- Northwestern Medicine researchers identified that brain-resident microglia cells uniquely metabolize fructose through the GLUT5 transporter to suppress immune responses and promote glioblastoma tumor growth. - Removing the fructose transporter in mouse models prevented tumor growth entirely and activated cancer-killing CD8+ T-cells, suggesting a novel therapeutic target for brain cancer treatment. - The findings reveal that fructose acts differently in the brain compared to other organs, suppressing rather than promoting inflammation, opening new avenues for improving immunotherapy responses in glioblastoma patients.
- Grace Therapeutics has received an FDA PDUFA target date of April 23, 2026, for its New Drug Application seeking approval of GTx-104, an intravenous nimodipine formulation for treating aneurysmal subarachnoid hemorrhage (aSAH). - The Phase 3 STRIVE-ON trial demonstrated that GTx-104 reduced clinically significant hypotension by 19% compared to oral nimodipine (28% vs 35%) and showed 29% more patients achieving favorable functional outcomes at 90 days. - The company reported $18.7 million in cash as of December 31, 2025, which management believes sufficient to sustain operations through at least 12 months while continuing pre-commercial planning activities. - aSAH represents a significant unmet medical need, accounting for approximately 5% of all strokes and affecting an estimated 42,500 U.S. hospital-treated patients annually, with no meaningful treatment innovation in nearly 40 years.
- Tempus AI has acquired Paige, an AI company specializing in digital pathology with FDA-cleared cancer detection applications and nearly 7 million digitized pathology slides. - The $81.25 million stock acquisition positions Tempus to build the largest oncology foundation model in history by combining datasets and AI capabilities. - The strategic move strengthens Tempus' position in the digital pathology market projected to reach $10 billion by 2030, enhancing drug discovery and personalized medicine capabilities. - Paige's global dataset from 45 countries and partnership with Memorial Sloan Kettering Cancer Center adds significant credibility and diversity to Tempus' AI platform.
- The NRG-CC003 phase II/III trial found that hippocampal avoidance during prophylactic cranial irradiation did not meet its primary endpoint of preserving delayed recall in small cell lung cancer patients. - Despite missing the primary endpoint, hippocampal avoidance significantly reduced overall neurocognitive function toxicity risk by 22% compared to standard radiation therapy. - The study demonstrated that hippocampal avoidance was noninferior for preventing brain metastases and showed no difference in overall survival or severe toxicity rates. - Results support hippocampal avoidance as a potential standard of care to reduce cognitive side effects while maintaining cancer control in small cell lung cancer patients.
- BioMendics has initiated the TAMES-02 clinical trial, a multicenter, randomized, double-blind, placebo-controlled study evaluating TolaSure, a first-in-class topical therapy for patients with generalized intermediate to severe Epidermolysis Bullosa Simplex. - The trial builds on promising TAMES-01 results and represents a potential breakthrough for the 30,000-50,000 patients worldwide affected by this rare inherited blistering disorder, which currently lacks disease-modifying treatment options. - TolaSure works by targeting mutant keratin proteins responsible for skin fragility, offering a novel mechanism to reinforce fragile keratinocytes and directly address the root cause of blister formation. - The study is conducted in partnership with Stanford University and Northwestern University, enrolling patients aged 4 and older with coverage for travel costs to ensure broad access across the United States and internationally.
- A multi-center phase 2 clinical trial led by Northwestern Medicine found that Duavee significantly reduced cell growth in breast tissue among 141 postmenopausal women with ductal carcinoma in situ (DCIS). - The drug, already FDA-approved for menopausal symptoms, was well tolerated by participants and did not affect quality of life during the four-week treatment period. - Duavee may offer a promising alternative for women at elevated breast cancer risk who experience menopausal symptoms but are typically advised against standard hormone therapies. - Researchers will present findings at the American Society of Clinical Oncology Annual Meeting, though larger studies with longer follow-up are needed before considering the drug for breast cancer prevention.
- Researchers developed predictive models that accurately distinguish mild, moderate, and severe community-acquired pneumonia in children aged 3 months to 14 years with a c-statistic of 0.82. - The multinational study analyzed 2,222 children across 73 emergency departments in 14 countries, finding that 5.4% developed severe pneumonia requiring intensive interventions. - Key risk factors for severe disease include hypoxemia, chest retractions, elevated vital signs, and abdominal pain, while congestion or rhinorrhea were protective against severe outcomes. - The models demonstrate superior performance compared to clinician judgment alone and could help reduce unnecessary hospitalizations while ensuring early identification of high-risk patients.
- Recent CDC data reveals a significant increase in anxiety rates among U.S. adults, rising from 15.6% in 2019 to 18.2% in 2022, with young adults aged 18-29 experiencing the highest prevalence at 26.6%. - Depression rates have similarly climbed from 18.5% to 21.4% during the same period, disproportionately affecting younger Americans, with nearly 27% of young adults reporting depressive symptoms. - The mental health crisis extends to children and adolescents, with anxiety increasing from 7.1% in 2016 to 10.6% in 2022, and depression rising from 3.2% to 4.6%, highlighting an urgent need for targeted interventions.
